Studies have suggested that the objective response rates of anti-PD-1 treatment (including nivolumab, pembrolizumab, and camrelizumab) increased to about 15%–20% for patients with HCC that were pretreated with sorafenib (7–9). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.